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Abstract
Background: The human leukocyte antigens (HLAs) are proteins found in the membranes of nearly all nucleated
cells. People with certain HLA antigens are more likely to develop certain autoimmune diseases. The aim of this
study was to determine the frequency of HLA-DRB1 in children with autoimmune hepatitis (AIH) as a risk factor for
occurrence, its relation to preceding hepatitis A infection and treatment outcome.
Subjects and methods: 25 children with AIH were subjected to HLA-DRB 1 typing performed by sequence
specific oligonucleotide probe technique and compared to HLA-DRB1 found in 548 normal populations.
Results: The most frequent alleles found in our children with AIH were HLA-DRB1*13 (36%), HLA-DRB1*04 (18%)
and HLA-DRB1*03 (14%). HLA-DRB1*13 was significantly more frequent in AIH patients compared to controls. In
type I AIH patients HLA-DRB1*13 was the most frequent allele (32.4%), followed by HLA-DRB1*04 in (20.6%) and
HLA-DRB1*03 in (14.7%), While in type II, the most frequent alleles were HLA-DRB1*13 in (40%), HLA-DRB1*07 (20%)
and HLA-DRB1*15 in (20%). HLA-DRB1*12 was significantly more frequent in AIH patients with positive Hepatitis A
IgM than in patients with negative hepatitis A IgM. No statistically significant difference between partial responders
and complete responders to treatment as regards HLA-DRB1 subtypes.
Conclusion: It is concluded from the previous study that HLA-DRB1*13 may be a susceptibility allele for the
occurrence of autoimmune hepatitis in our population. HLA-DRB1*07 and HLA-DRB1*15 may be susceptibility
alleles for occurrence of autoimmune hepatitis type 2. HLA-DRB1*12 association with AIH in patients triggered by
hepatitis A needs further studies.
Introduction
Auto-immune hepatitis (AIH) is a chronic liver disorder
of unknown cause that leads to cirrhosis and liver fail-
ure when untreated. The disease usually affects females
and is characterized by the presence of circulating auto
antibodies and by severe interface hepatitis on liver
biopsy [1].
Two types of AIH have been proposed on the basis of
s e r o l o g i cm a r k e r s ,t y p e1 - A I Hi st h em o s tc o m m o n
form worldwide while type 2-AIH occurs mainly in chil-
dren and in Europe [2].
Although the etiology of AIH is unknown, both
genetic and environmental factors are involved in its
expression [3]. Strong evidence suggests that defects in
immunologic control of auto reactivity play a role in
AIH pathogenesis [4].
HLA antigens are the major determinants used by the
body’s immune system for recognition and differentia-
tion of self from non-self. There are many different
major histocompatibility (HLA) proteins, and each per-
son possesses only a small, relatively unique set that is
inherited from their parents [5].
Autoimmune diseases are the result of interplay
between predisposing genes and triggering environmental
factors, leading to loss of self-tolerance and an immune-
mediated destruction of autologous cells and/or tissues.
Genes in the HLA complex are among the strongest pre-
disposing genetic factors [6]. In auto-immune hepatitis
patients, HLA DRB positive patients are more likely to
have the disease than other patients [7]. Although, drugs
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and trigger AIH, primarily viruses have been studied in
this context [8].
The aim of this study was to determine the frequency
of HLA-DRB1 in patients with autoimmune hepatitis as
a risk factor for occurrence, its relation to preceded
HAV infection, and treatment outcome.
Patients and Methods
This study was conducted on 25 children with AIH
recruited from patients regularly attending the Hepatol-
ogy Clinic, Children’s Hospital; Ain Shams Faculty of
Medicine and Prof. Yassin Abd El-Ghaffar Charity Cen-
tre for Liver Diseases and Research, both are tertiary
referral centers. It was performed according to the
recommendations of the Ethics Committee of Ain
Shams University Hospitals. An informed consent was
obtained from the children’s guardians.
The diagnosis of AIH was based on the International
Scoring Criteria for auto-immune hepatitis [9] evaluated
before the start of any immunosuppressant treatment.
Patients with primary sclerosing cholangitis or overlap
syndrome were excluded from the study.
All patients included were subjected to proper history
taking, thorough clinical examination
- Laboratory investigations were done for all patients
and included complete blood count, serum ALT, AST,
total bilirubin, direct bilirubin, prothrombin time, serum
albumin and serum protein electrophoresis.
-Abdominal ultrasound was done for all patients and
liver biopsy was done for initial evaluation in 19 patients
and after the start of treatment and stabilization of the
bleeding profile in 6 patients.
- HLA-DRB typing by sequence specific oligonucleo-
tide probe (SSOP) technique in which 5 ml blood on
sterile EDTA tubes was collected from each patient.
DNA extraction was done using the DNA isolation kit
(minikit, Qiagen, Hilden Germany). HLA-DRB typing
was done using Dynal RELITM SSO HLA-DRB typing
kit (Dynal Biotech Ltd., UK).
The principal is based on three major processes:
1) PCR amplification reactions which were done using
the thermal cycler to produce an amplified biotinylated
DNA sequence termed an amplicon utilizing biotiny-
lated primers. PCR was done applying the following pro-
tocol: denaturation at 95 degree for 15 seconds, primer
annealing at 60 degree for 45 seconds and extension at
72 degree for 15 seconds. This process was repeated for
35 cycles. 2) Hybridization step in which the amplicons
were chemicallly denatured to form single stranded
DNA, these were added to nylon membrane that con-
tains an array of immobilized sequence-specific oligo-
neuclotide (SSO) probes. The biotin-labeled amplicons
then bind (hybridise) to those SSO probes that contain
a complementary target sequence and thus “captured”
on to membrane strip. 3) Detection of the amplicon-
probe complex was done using a colorimetric reaction.
Interpretation of the results was done using the Dynal
RELITM SSO pattern matching program [10].
HLA typing of our patients was compared to a pub-
lished study done by Khalil et al [11] which was per-
formed in Ain Shams University Specialized Hospital,
where 548 Egyptians were investigated for the most fre-
quent HLA-DR alleles among the Egyptian population
using sequence specific oligonucleotide probe (SSOP)
technique. It is considered a weakness point to use con-
trols from different study, yet the included subjects
represent the normal population in our country as this
hospital is a referral center.
- Response to treatment was evaluated as follows
“Complete remission” is indicated by the absence of
symptoms, and return of serum ALT or AST, bilirubin
and immunoglobulin values to normal within 1 year, or
histologic improvement to normal or minimal inflam-
matory activity on liver biopsy. “Treatment failure” is
defined as deterioration in a patient’s clinical condition,
laboratory tests, or histologic features despite intensive
therapy.” Incomplete response to treatment” is defined
as an improvement that is insufficient to satisfy remis-
sion criteria [9].
Statistical methods
SPSS statistical software package was used for data analy-
sis. Date was expressed as Mean ± SD for quantitative
measures and both number and percentage for categorized
data. Comparison between two independent means for
parametric data was done using student test. Comparison
between two independent groups for non-parametric data
was done using Wilcoxon Rank Sum test. Wilcoxon
signed rank test for comparison between two dependent
groups for non-parametric data. Chi-square test used to
study the association between 2 variables, or comparison
between 2 independent groups as regards the categorized
data. The probability of error at 0.05 was considered
significant.
Results
The included children with AIH were 17 females (68%)
and 8 males (32%), their ages ranged from 6 to 18 years
with a mean of 13.2 ± 3.8 years. The mean duration of
illness was 4.4 ± 3.1 years.
The clinical, biochemical, and histological features at
presentation are reported in (Table 1). All our patients
were symptomatic at presentation and the most frequent
type of onset was acute hepatitis with cholestatic jaun-
dice and elevated liver enzymes (64%) while chronic pre-
sentation with cirrhotic liver and portal hypertension
was found in 36%. Type 1 AIH was predominant in
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68%, while type 2 was characterized by the presence of
anti- LKM in only 20% and 12% were seronegative,
according to the International Scoring Criteria for auto-
immune hepatitis, the diagnosis was definite in 88% and
probable in 12%. Concomitant autoimmune thyroiditis
was detected in 3 (15%) children out of 20, who were
subjected to thyroid auto antibodies testing.
Nearly quarter of our patients were presented at the
beginning with a picture of acute hepatitis that was diag-
nosed as hepatitis A evident by positive hepatitis A IgM.
Based on the clinical course as those patients had unu-
sual prolonged (more than one month) or protracted
course of hepatitis A, the diagnosis turned to be AIH
according to the International Autoimmune Hepatitis
Group’s system. They all had type 1 AIH. The rest of the
patients were either vaccinated or negative for HAV IgM.
L i v e rb i o p s ys h o w e dt h a t9 2 %o ft h e mh a ds e v e r e
inflammation, while fibrosis was present 72% and cir-
rhosis was evident at presentation in 32%.
Complete response was achieved in 64% of the
included children while 28% only partial response could
be achieved and no one showed failure to response how-
ever 8% were non compliant to treatment.
The most frequently observed class II alleles in the
group of patients were HLA-DRB1*13 as it constituted
36% of alleles, then HLA-DRB1*04( 18%), HLA-
DRB1*03 ( 14%). The most frequent alleles found in the
control group were HLA-DRB1*03 ( 19%) then HLA-
DRB1*13 and HLA-DRB1*04 as each constituted 16% of
alleles. Only HLA-DRB1*13 was significantly prevalent
in our patients with AIH (Table 2).
Although HLA-DRB1*13 was the most frequent allele
in type 2 AIH, yet statistically HLA-DRB1*07, HLA-
DRB1*15 alleles were significantly more frequent in type
2 AIH versus type 1 (table 3). The group of children in
which the diagnosis of AIH was probable according to
the scoring system showed that their HLA-DRB1 allels
were 3/13 in one patient, 4/13 in the second one and
1/13 in the third one which were not different from
patients with confirmed diagnosis.
HLA-DRB1*13 was the most prevalent allele in auto-
immune hepatitis patients with positive HAV IgM in
this study however HLA-DRB1*12 was the only statisti-
cally significant allele in those patients compared to
patients with negative hepatitis A IgM and no significant
difference as regards other alleles was found (Table 4).
Although HLA-DRB1*03 was frequently found in par-
tial responders to treatment and HLA-DRB1*04 was fre-
quently found in complete responders, yet this was not
of statistical significance neither do other HLA-DRB1*
subtypes.
Discussion
Autoimmune hepatitis is a chronic hepatitis of unknown
etiology characterized by immunologic and auto immu-
nologic features [12]. High-resolution DNA-based tech-
niques have indicated that the principal susceptibility
factors for autoimmune hepatitis associated with ASMA
and ANA expression reside on the DRB1 gene [13].
There is substantial evidence favoring hepatitis A virus
(HAV) as an etiological factor in AIH. This includes
individual case reports of persistent hepatic inflamma-
tion, with serological and histological features of AIH
following proven infection with HAV, and the develop-
ment of autoantibodies to hepatic constituents during
and after HAV infection [14].
The aim of this study was to determine the frequency
of HLA-DRB1 in patients with autoimmune hepatitis as
a risk factor for occurrence, its relation to preceded
HAV infection, and treatment outcome.
Type 1 AIH is the most common form worldwide,
while Type 2 AIH occurs mainly in children and in Eur-
ope [15]. However in our study although performed on
children, 68% were categorized as type 1 AIH and 20%
as type 2. This disagree with Muratori et al [16], who
published the Bologna experience of autoimmune hepa-
titis in Italy and reported that among 28 included chil-
dren 24 had AIH type 2 but this can be explained by
different ethnic background.
Table 1 Clinical, biochemical, and histological features of
autoimmune hepatitis at presentation
Sex (F/M) 17/8
Type 1/type 2/seronegative AIH 17/5/3
Presentation:
Acute 16 (64%)
Chronic 9 (36%)
ALT(IU/L) × normal 10 × n
AST(IU/L) × normal 9 × n
Alb(g/dL) 3.5 ± 0.8
Gammaglobulin (g/dl) 3.3 ± 1.8
Total Bilirubin (mg/dl) 4.9 ± 2.8
Direct bilirubin (mg/dl) 3.1 ±1.95
ANA 9 (36%)
ASMA 17 (68% )
Anti-LKM 5 (20%)
Autoimmune thyroiditis ( 20) 3 (15%)
Hepatitis A IgM +ve 6 (24%)
Liver biopsy:
Interface hepatitis 23 (92% )
Fibrosis 18 (72%)
Cirrhosis 7 (32%)
Complete response 16 (64%)
Partial response 7 (28%)
Treatment failure 0
Non compliance 2 (8%)
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was acute marked by signs and symptoms of acute
hepatitis, whereas in the remaining 36% the patients
presented with overt chronicl i v e rd i s e a s ew i t hp o r t a l
hypertension.
The modes of presentation differ largely in different
studies as Mieli-Vergeni and Vergani [17] reported
that the course of the disease may be fluctuating with
flares and spontaneous remission, a pattern that may
result in delayed referral and diagnosis. Kogan et al
[18] found that 34% of patients were asymptomatic at
presentation and typically, discovered during routine
general medical examination that includes the screening
of liver tests and Muratori et al [16] in their study
found that 42.8% of children patients were presented
with acute hepatitis while 14% were asymptomatic and
7.2% of their patients had insidious onset. The higher
percentage of symptomatic patients in our study can be
explained by the fact that all the included patients were
recruited from referral centers so they are likely to
represent those with more severe disease.
Cirrhosis was present in the liver biopsy in 32% and
fibrosis in 72% of the patients who were biopsied for
histopathological diagnosis. Ferrari et al [19] stated that
the presence of overt cirrhosis in one quarter of patients
at the time of diagnosis suggests that the disease has a
subclinical expression lasting several months or even
years.
Nearly quarter of our patients were presented at the
beginning with acute hepatitis A as evident by positive
hepatitis A IgM and the diagnosis turned to be AIH in
those patients based on the clinical course and accord-
ing to the International Autoimmune Hepatitis Group’s
system. HLA-DRB1*12 was statistically significant in
those patients than patients with negative hepatitis A
IgM and no significant difference as regards other alleles
was found, but due to small number, this needs further
confirmation.
Attention has focused on the theory of molecular
mimicry between the infectious particle and the liver
constituent against which the resulting antibodies react.
Such mimicry between a viral and a hepatic epitope has
been demonstrated [20]. In relatives of patients with
AIH, Vento et al [21] demonstrated an intrinsic defect in
suppressor-inducer T-cells mediating immune reactivity
to a liver antigen (asialoglycoprotein receptor-ASPGR),
Table 2 Comparison between the studied cases and control group as regards HLA-DRB1*
Alleles No of alleles in cases = 50 No of alleles in controls = 1096 P
HLA-DRB1* No % No %
01 3 6 55 5 >0.05
03 7 14 214 19 >0.05
04 9 18 175 16 >0.05
07 3 6 66 6 >0.05
08 2 4 22 2 >0.05
11 4 8 132 12 >0.05
12 1 2 22 2 >0.05
13 18 36 175 16 <0.001
15 3 6 77 7 >0.05
Table 3 Comparison between Types of AIH as regards HLA-DRB1*
Alleles Type 1 (no = 34) Type 2 (no = 10) Sero -ve (no = 6) Type 1 vs. Type 2 Type 1 vs. sero -ve Type 2 vs. sero -ve
HLA-DRB1* No % No % No % P P P
1 2 5.9 0 0 1 16.7 >0.05 >0.05 >0.05
3 5 14.7 1 10 1 16.7 >0.05 >0.05 >0.05
4 7 20.6 1 10 1 16.7 >0.05 >0.05 >0.05
7 1 2.9 2 20 0 0 <0.05 >0.05 >0.05
8 2 5.9 0 0 0 0 >0.05 >0.05 >0.05
11 4 11.8 0 0 0 0 >0.05 >0.05 >0.05
12 1 2.9 0 0 0 0 >0.05 >0.05 >0.05
13 11 32.4 4 40 3 50 >0.05 >0.05 >0.05
15 1 2.9 2 20 0 0 <0.05 >0.05 >0.05
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clinical exposure (seroconversion to HAV) with a simul-
taneous rise in anti-ASGPR antibodies. Urganci et al
[22] report a 6 year old boy with autoimmune hepatitis
and autoimmune hemolytic anemia following HAV infec-
tion and Tabak et al [23] reported a 21-year-old female
with acute HAV that turned to be AIH and concluded
that, prolonged HAV infection and AIH may not only
trigger each other but also deteriorate the liver histology.
This raises the question of the ability of hepatitis A
vaccine to protect genetically susceptible patients (other
family members) from developing autoimmune hepatitis
however; Berry and Smith-Laing [24] reported a case
of hepatitis A vaccine associated with autoimmune
hepatitis and concluded that the recrudescence of this
case following vaccination with inactivated HAV adds to
the evidence that HAV may trigger autoimmunity
against the liver and should not be interpreted as a side
effect based on the vaccine’s track record of safety, but
reveals potential connections between two apparently
disparate liver pathologies.
HLA-DRB1*13 was a susceptibility allele for the occur-
rence of AIH in our population, in accordance Bitten-
court et al [25] as they found that genetic susceptibility
to AIH linked to HLA-DRB1*13 but, HLA-DRB1*03
allele was also found in the Brazilian population and indi-
cated that different HLA antigens confer the susceptibil-
ity of AIH types I and II. In Caucasian patients, those
with HLADR3 and DR4 are independently susceptible to
AIH while, DR4 is predominant in Japanese patients and
there are no Japanese patients with DR3 [26].
Fainboim and associates [27] stated that HLA
DRB1*13 is a risk factor for type 1 AIH in South Amer-
ica, and HLA DRB1*03 and DRB1*04 are independent
risk factors for the disease in white North Americans.
Moreover they stated that HLADRB1*13 has been
implicated in the clearance of viral infection and in the
immune response against viral proteins. Its presence
may select individuals for protracted exposure to viral
and hepatic antigens that favor development of the dis-
ease. The predominant association of HLA DRB1*13
with type 1 autoimmune hepatitis in Brazil and Argen-
tina suggests that HLA DRB1*13 favors the presentation
of triggering antigens that are common to this region,
and the hepatitis A virus may be one of several such
agents, may be this can explain the prevalence of type 1
AIH among our children and not type 2 as we are also
endemic area for Hepatitis A.
There was no statistically significant difference
between partial responders and complete responders to
treatment of AIH according to HLA-DRB1*. However
Montano-Loza and associates [28] found that the dete-
rioration during conventional corticosteroids therapy
occurs infrequently in patients with definite type I auto-
immune hepatitis at presentation. Treatment failure is
associated with onset at an early age, acute presentation,
hyperbilirubinemia and HLA-DRB1*03. Muratori et al
[16] found that type I and type II AIH are one and the
same disease, has similar features in male and female
patients, HLA-DRB1*04 positive patients are more likely
to achieve complete remission. Continuous on low dose
steroids are necessary to maintain remission, signifi-
cantly reducing the risk of disease progression.
It was concluded from this study that HLA-DRB1*13
may be a susceptibility allele for the occurrence of auto-
immune hepatitis in our population. HLA-DRB1*07 and
HLA-DRB1*15 may be susceptibility alleles for occur-
r e n c eo fa u t o i m m u n eh e p a t i t i st y p e2 .H L A - D R B 1 * 1 2
association with AIH in patients triggered by hepatitis A
needs further studies.
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Table 4 Comparison between patients with Hepatitis A
(+ve IgM) and patients with Hepatitis A (-ve IgM) as
regards HLA-DRB1*
Alleles Hepatitis A +ve IgM
No = 12
Hepatitis A -ve IgM
No = 38
P
HLA-DRB1* No % No %
01 1 8.3 2 5.3 >0.05
03 0 0 7 18.4 >0.05
04 1 8.3 8 21 >0.05
07 1 8.3 2 5.3 >0.05
08 1 8.3 1 2.6 >0.05
11 2 16.7 2 5.3 >0.05
12 1 8.3 0 0 <0.05
13 4 33.3 14 36.8 >0.05
15 1 8.3 2 5.3 >0.05
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